Podcast: PrEP for Men and TGW
Key Decisions in HIV Care: PrEP Considerations in Cisgender Men and Transgender Women

Released: March 25, 2022

Expiration: March 24, 2023

Latesha Elopre
Latesha Elopre, MD, MSPH
Karine Lacombe
Karine Lacombe, MD, PhD

Activity

Progress
1
Course Completed

In this episode from the series “Key Decisions in HIV Care,” Latesha Elopre, MD, MSPH, and Karine Lacombe, MD, PhD, discuss important considerations for PrEP in cisgender men and transgender women, including:

  • Discussion of the PrEP gap and racial and gender disparities in PrEP access
  • CDC, EACS, and WHO guidance on PrEP eligibility
  • PrEP regimens currently recommended for adults and adolescents including FTC/TDF daily, FTC/TAF daily, and long-acting cabotegravir
  • Data from clinical trials on the efficacy of FTC/TDF daily for men including Partners PrEP, TDF2, iPrEx, iPrEx OLE, and PROUD
  • Data from the ANRS IPERGAY study on the use of FTC/TDF on demand
  • Data from the DISCOVER trial on the use of FTC/TAF for PrEP
  • Data from the HPTN 083 study on the use of long-acting cabotegravir as PrEP for cisgender men
  • Clinical monitoring and considerations during PrEP use